Use of Sirolimus, an mTOR Inhibitor, to Treat Sarcoidosis in Multiple Systems
Open Access
- 25 September 2025
- journal article
- review article
- Published by Springer Nature in Journal of Cardiovascular Translational Research
- Vol. 18 (6) , 1893-1901
Abstract
Sarcoidosis is a heterogenous, multi-systemic granulomatous disease with highly variable incidence (5–40/100,000) and a disproportionate mortality burden in those presented with pulmonary fibrosis or cardiac involvement. Yet, current management strategies are symptom-targeting, not always effective and come with significant side effects. Preclinical murine models of sarcoidosis have shown that aberrant mTORC1 activation promotes macrophage-driven inflammation and disrupts autophagic clearance, sustaining granuloma formation. Sirolimus, a selective mTORC1 inhibitor, restores autophagy and macrophage function, offering a targeted therapeutic approach. Herein, we present the first comprehensive review of all known clinical cases of sirolimus use in different forms of sarcoidosis. All studies reviewed suggest that sirolimus may be an effective, yet safe, mechanism-targeting therapy for patients with sarcoidosis not responding to conventional pharmacological interventions. Graphical AbstractKeywords
This publication has 39 references indexed in Scilit:
- Utility of Mechanistic Target of Rapamycin Inhibitors in Cardiac SarcoidosisJournal of Cardiac Failure, 2024
- Efficacy and safety of mTOR inhibition in cutaneous sarcoidosis: a single-centre trialThe Lancet Rheumatology, 2024
- Sarcoidosis incidence after mTOR inhibitor treatmentSeminars in Arthritis and Rheumatism, 2022
- Sarcoidosis and the mTOR, Rac1, and Autophagy TriadTrends in Immunology, 2020
- Inhibition of the mammalian target or rapamycin (mTOR): a potential therapeutic strategy for multiple system atrophyClinical Autonomic Research, 2020
- Off-Label Use of Sirolimus and Everolimus in a Pediatric Center: A Case Series and Review of the LiteraturePediatric Drugs, 2019
- Long term follow-up of infliximab efficacy in pulmonary and extra-pulmonary sarcoidosis refractory to conventional therapySeminars in Arthritis and Rheumatism, 2013
- A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosisJournal of the American Academy of Dermatology, 2013
- Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKBMolecular Cell, 2006
- Sirolimus, a New, Potent Immunosuppressive AgentPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1997